Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Código QR

Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Abstract Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMAs) promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mujdat Zeybel, Ozlem Altay, Muhammad Arif, Xiangyu Li, Hong Yang, Claudia Fredolini, Murat Akyildiz, Burcin Saglam, Mehmet Gokhan Gonenli, Dilek Ural, Woonghee Kim, Jochen M Schwenk, Cheng Zhang, Saeed Shoaie, Jens Nielsen, Mathias Uhlén, Jan Borén, Adil Mardinoglu
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	CMA multi‐omics NAFLD systems biology Biology (General) QH301-705.5 Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/458a964c837f412a952dd9635ecd9b5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease
por: Szanto KB, et al.
Publicado: (2019)

Changes in Serum Nesfatin-1 After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Nonalcoholic Fatty Liver Disease
por: Yang K, et al.
Publicado: (2020)

Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease
por: Fan Y, et al.
Publicado: (2021)

Liver Stiffness Measurement by Using Transient Elastography in Bangladeshi Patients with Type 2 Diabetes Mellitus and Ultrasonography-Diagnosed Nonalcoholic Fatty Liver Disease
por: Alam MS, et al.
Publicado: (2021)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome G, et al.
Publicado: (2020)

Gender differences in relation to hyperuricemia and nonalcoholic fatty liver disease among Type 2 diabetics in Telangana, India
por: Usha Sree Puneem, et al.
Publicado: (2021)

Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
por: Xu H, et al.
Publicado: (2019)

Relationship Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease (NAFLD) in a Developing Country: A Cross-Sectional Study
por: Abo-Amer YEE, et al.
Publicado: (2020)

Analysis Of Risk Factors For Nonalcoholic Fatty-Liver Disease In Hepatitis B Virus Infection: A Case–Control Study
por: Azarkar G, et al.
Publicado: (2019)

Hepatoprotective Effects of Tribulus terrestris Hydro-Alcholic Extract on Non-Alcoholic Fatty Liver- Induced Rats
por: Almasi,Fatemeh, et al.
Publicado: (2017)

Correlation between Non-Alcoholic Fatty Liver Disease (NAFLD) fibrosis score (NFS) with Left Ventricular Mass Index (LVMI) in patients with NAFLD
por: Tri Ferry Rachmatullah, et al.
Publicado: (2021)

Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
por: Sandip Mukherjee, et al.
Publicado: (2021)

Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis
por: Sun Y, et al.
Publicado: (2019)

Aqueous Metabolite Trends for the Progression of Nonalcoholic Fatty Liver Disease in Female Bariatric Surgery Patients by Targeted <sup>1</sup>H-NMR Metabolomics
por: Emma J. Robinson, et al.
Publicado: (2021)

Network Pharmacology-Based Analysis of Pogostemon cablin (Blanco) Benth Beneficial Effects to Alleviate Nonalcoholic Fatty Liver Disease in Mice
por: Yizhe Cui, et al.
Publicado: (2021)

Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: An effect of glucosylceramide accumulation
por: Zhiqiang Li, et al.
Publicado: (2021)

Effect of Probiotic Supplementation on Sprague Dawley Rat Liver Histopathology Fed by High Fat High Fructose Diet
por: Ninung Rose Diana Kusumawati, et al.
Publicado: (2021)

Integrative Analysis of Metabolome and Microbiome in Patients with Progressive Alcohol-Associated Liver Disease
por: Bei Gao, et al.
Publicado: (2021)

Dietary Intervention Reverses Fatty Liver and Altered Gut Microbiota during Early-Life Undernutrition
por: K. C. Bauer, et al.
Publicado: (2020)

Role of Ferroptosis in Non-Alcoholic Fatty Liver Disease and Its Implications for Therapeutic Strategies
por: Han Zhang, et al.
Publicado: (2021)

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases
por: Rocío Gallego-Durán, et al.
Publicado: (2021)

Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial
por: Kourosh Masnadi Shirazi, et al.
Publicado: (2021)

Machine Learning-Based Identification of Potentially Novel Non-Alcoholic Fatty Liver Disease Biomarkers
por: Roshan Shafiha, et al.
Publicado: (2021)

Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum
por: Chen HW, et al.
Publicado: (2021)

The Association Between Different Obesity Phenotypes and Liver Fibrosis Scores in Elderly Individuals with Fatty Liver in Taiwan
por: Lee YS, et al.
Publicado: (2021)

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
por: Ganguli S, et al.
Publicado: (2019)

The Impact of Vitamin D in Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Patients with Morbid Obesity
por: Borges-Canha M, et al.
Publicado: (2021)

Gut Microbiota Reshaped by Pectin Treatment Improves Liver Steatosis in Obese Mice
por: Camille Houron, et al.
Publicado: (2021)

The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
por: Siyu Yu, et al.
Publicado: (2021)

The Circulating Micro-RNAs (−122, −34a and −99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases
por: Hendy OM, et al.
Publicado: (2019)

A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis
por: Jian Li, et al.
Publicado: (2021)

Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
por: Gwyneth Shook Ting Soon, et al.
Publicado: (2021)

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Daniela Maria Tanase, et al.
Publicado: (2021)

Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease
por: Ahmed Z, et al.
Publicado: (2018)

Plant-derived oleanolic acid ameliorates markers associated with non-alcoholic fatty liver disease in a diet-induced pre-diabetes rat model
por: Gamede M, et al.
Publicado: (2019)

A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic fatty liver disease
por: Hong Yang, et al.
Publicado: (2021)

Network Pharmacology Exploration Reveals Anti-Apoptosis as a Common Therapeutic Mechanism for Non-Alcoholic Fatty Liver Disease Treated with Blueberry Leaf Polyphenols
por: Cai-Ren Wang, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress
por: Sue Shea, et al.
Publicado: (2021)

The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease
por: Yan J, et al.
Publicado: (2017)

The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease
por: Hao Xu, et al.
Publicado: (2021)